A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

• ClinicalTrials.gov Identifier: NCT02810951
• Recruitment Status: Terminated
• First Posted: June 23, 2016
• Results First Posted: September 16, 2021
• Last Update Posted: February 8, 2023
• Sponsor: Castle Creek Biosciences, LLC.
• Information provided by (Responsible Party): Castle Creek Biosciences, LLC.

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety of FCX-007, evaluate Type VII collagen (COL7) expression and the presence of anchoring fibrils and to analyze wound healing as a result of FCX-007 administration in subjects with recessive dystrophic epidermolysis bullosa (RDEB). Funding Source- FDA OOPD

Condition or disease	Intervention/treatment	Phase
Epidermolysis Bullosa Dystrophica, Recessive	Genetic: FCX-007	Phase 1; Phase 2

Detailed Description:

RDEB is a rare skin and connective tissue disease characterized clinically by skin fragility with easy blistering, erosion and scarring of skin and mucous membranes, and caused by the deficiency of the protein type VII collagen (COL7). The objective of this study is evaluate the safety of FCX-007 intradermal injections in RDEB subjects. Additionally, the trial will evaluate COL7 expression, the presence of anchoring fibrils, as well evidence of wound healing.

Approximately twelve subjects are expected to enroll in the Phase I/II trial. Phase I will enroll approximately six adult subjects. Phase II will enroll approximately six subjects both adults and pediatric (aged seven (7) years or older). All subjects will receive FCX-007 to one or more paired target RDEB wounds. Proof of mechanism will be monitored through digital photography of target wounds and assays conducted on biopsies taken from intact skin sites where FCX-007 is administered.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 6 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
• Actual Study Start Date: July 1, 2016
• Actual Primary Completion Date: September 29, 2020
• Actual Study Completion Date: April 18, 2022

Arms and Interventions

Arm

Intervention/treatment

Experimental: FCX-007; In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B. In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects. All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results. One wound in each target wound pair will be used as control for efficacy and safety evaluations.

Genetic: FCX-007; FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional COL7. FCX-007 cell suspension is injected intradermally.; Other Name: Genetically-Modified Autologous Human Dermal Fibroblasts

Outcome Measures

Primary Outcome Measures :

1. Adverse Events [ Time Frame: 52 weeks post treatment ]
   Number of subjects with adverse events.

Secondary Outcome Measures :

1. Complete Wound Closure [ Time Frame: Through Week 52 ]
   Percentage of target wounds achieving complete wound closure (greater than 90%) at all post-baseline visits

Eligibility Criteria

• Ages Eligible for Study: 7 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

1. Age

   1. Phase I: Eighteen (18) years or older.
   2. Phase II: Seven (7) years or older.
2. Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB)

Key Exclusion Criteria:

1. Medical instability limiting ability to travel to the investigative center.
2. Active infection with HIV, hepatitis B or hepatitis C or evidence of other systemic infection
3. Current evidence of metastatic squamous cell carcinoma at the site to be injected
4. Clinically significant abnormal laboratory result or other significant clinical abnormalities
5. Receipt of a chemical or biological study product for the specific treatment of RDEB in the past six months

Contacts and Locations

Locations

United States, California

Stanford University

Stanford, California, United States, 94305

United States, Colorado

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Sponsors and Collaborators

Castle Creek Biosciences, LLC.

  Study Documents (Full-Text)

Documents provided by Castle Creek Biosciences, LLC.:

Study Protocol and Statistical Analysis Plan  [PDF] October 29, 2019

More Information

• Responsible Party: Castle Creek Biosciences, LLC.
• ClinicalTrials.gov Identifier: NCT02810951
• Other Study ID Numbers: FI-EB-001; FD-R-6113-01 ( Other Grant/Funding Number: Office of Orphan Products Development )
• First Posted: June 23, 2016
• Results First Posted: September 16, 2021
• Last Update Posted: February 8, 2023
• Last Verified: February 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Castle Creek Biosciences, LLC.:

RDEB

Additional relevant MeSH terms:

Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Skin Abnormalities; Congenital Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases; Skin Diseases, Vesiculobullous; Collagen Diseases; Connective Tissue Diseases